Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-VCAM-1 Antibody-APC (5S896) is a APC-conjugated Rabbit antibody targeting VCAM-1. Anti-VCAM-1 Antibody-APC (5S896) can be used in FCM.
Description | Anti-VCAM-1 Antibody-APC (5S896) is a APC-conjugated Rabbit antibody targeting VCAM-1. Anti-VCAM-1 Antibody-APC (5S896) can be used in FCM. |
Ig Type | Monoclonal Rabbit IgG |
Clone | 5S896 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human VCAM1 expression on HUT78 cells. Cells were stained with APC-conjugated anti-Human VCAM1. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | FCM |
Recommended Dose | 5 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Human VCAM-1 / CD106 (rh VCAM-1 / CD106; NP_001069.1Met1-Pro697) and conjugated with APC under optimum conditions, the unreacted APC was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
Research Background | Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | APC |
Others Formats | Unconjugated/FITC/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Human VCAM-1 / CD106 Protein |
Antigen Species | Human |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.